FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG ShortageBusiness Wire • 02/19/25
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In SituBusiness Wire • 02/13/25
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung CancerBusiness Wire • 01/29/25
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In SituBusiness Wire • 01/27/25
IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UKZacks Investment Research • 01/17/25
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the AgencyBusiness Wire • 01/15/25
ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United KingdomBusiness Wire • 01/15/25
ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term SuccessSeeking Alpha • 12/13/24
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public OfferingGlobeNewsWire • 12/12/24
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data FulfillmentPRNewsWire • 11/21/24
Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a BetZacks Investment Research • 11/19/24
ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False StatementsPRNewsWire • 11/19/24
ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 MonthsBusiness Wire • 11/19/24
ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025Seeking Alpha • 10/28/24
ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock?Zacks Investment Research • 10/28/24
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio's CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin LymphomaBusiness Wire • 10/24/24
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBioBenzinga • 10/23/24